

HIV

alimatravir (MK-8527) MSD

cabotegravir 4-monthly ViiV

islatravir/lenacapavir MSD/Gilead

cabotegravir/lenacapavir ViiV/Gilead

islatravir/ulonivirine MSD

VH-184 ViiV

● islatravir/doravirine MSD

lenacapavir yearly Gilead

VH-499 ViiV


GS-3242 Gilead

GS-1720/GS4182 Gilead

TAF/EVG insert CONRAD

● Monoclonal antibodies for HIV post-natal prophylaxis

Multiple innovators



TUBERCULOSIS

quabodepistat Otsuka

alpibectir GSK/Bioversys

bedaquiline long-acting J&J

sudapyridine Shanghai Jiatan Biotech

macozinone EPFL

ganfeborole GSK

delpazolid LegoChem Bio



VIRAL HEPATITIS

HEPATITIS B

bepirovirsen GSK

HEPATITIS C

bemnifosbuvir/ruzasvir Atea



MALARIA

● MicroCoat AS/AQ FluidPharma



RESPIRATORY SYNCYTIAL VIRUS

● clesrovimab MSD

● nirsevimab AstraZeneca/Sanofi

● retavibart Trinomab

● ziresovir Ark Biosciences



SICKLE CELL DISEASE

● etavopivat Novo Nordisk

● mitapivat Agios Pharmaceuticals

● ndec Novo Nordisk

● tebapivat Agios Pharmaceuticals



CYSTIC FIBROSIS

● elexacaftor/ivacaftor/tezacaftor Vertex

● deutivacaftor/tezacaftor/vanzacaftor Vertex



ONCOLOGY

MULTIPLE CANCER INDICATIONS

Immune checkpoint inhibitors

Multiple innovators

including

● pembrolizumab MSD

LUNG CANCER

aumolertinib Hansoh Pharma

osimertinib AstraZeneca

adagrasib Bristol Myers Squibb

lazertinib J&J

sotorasib Amgen

BREAST CANCER

abemaciclib Eli Lilly

ribociclib Novartis

trastuzumab SQ Roche

CHRONIC LYMPHOCYTIC LEUKAEMIA

zanubrutinib BeOne

PROSTATE CANCER

apalutamide Janssen

darolutamide Bayer

LOW-GRADE GLIOMAS

● dabrafenib/trametinib

Novartis



DIABETES, CARDIOVASCULAR & METABOLIC DISORDERS

Incretin-based therapies (incl. GLP1 RA)

Multiple innovators

including

orforglipron Eli Lilly

● semaglutide Novo Nordisk

● tirzepatide Eli Lilly

retatrutide Eli Lilly

● Insulin analogues

Multiple innovators

cardiovascular fixed-dose combination therapies

Multiple innovators

PRIORITY LIST

WATCHLIST

● paediatric application

June 2026